How to buy Orgenesis stock

Orgenesis Inc is a biotechnology business based in the US. Orgenesis shares (ORGS) are listed on the NASDAQ and all prices are listed in US Dollars. Orgenesis employs 111 staff and has a trailing 12-month revenue of around 0.00.

Orgenesis share price

Use our graph to track the performance of ORGS stocks over time.

Orgenesis shares at a glance

• Key figures

Information last updated 2021-04-23.

52-week range	$4.30 - $8.30
50-day moving average	$6.23
200-day moving average	$5.62
Wall St. target price	$9.00
PE ratio	17.517
Dividend yield	N/A (0%)
Earnings per share (TTM)	$0.29

Buy Orgenesis shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Orgenesis stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Orgenesis Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Orgenesis under- or over-valued?

Valuing Orgenesis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Orgenesis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Orgenesis's P/E ratio

Orgenesis's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 18x. In other words, Orgenesis shares trade at around 18x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Orgenesis financials

Revenue TTM	$7.7 million
Gross profit TTM	$7.7 million
Return on assets TTM	-69.85%
Return on equity TTM	-211.96%
Profit margin	14.51%
Book value	$2.18
Market capitalisation	$130 million

TTM: trailing 12 months

Shorting Orgenesis shares

There are currently 753,012 Orgenesis shares held short by investors – that's known as Orgenesis's "short interest". This figure is 37.8% up from 546,620 last month.

There are a few different ways that this level of interest in shorting Orgenesis shares can be evaluated.

Orgenesis's "short interest ratio" (SIR)

Orgenesis's "short interest ratio" (SIR) is the quantity of Orgenesis shares currently shorted divided by the average quantity of Orgenesis shares traded daily (recently around 189675.56675063). Orgenesis's SIR currently stands at 3.97. In other words for every 100,000 Orgenesis shares traded daily on the market, roughly 3970 shares are currently held short.

However Orgenesis's short interest can also be evaluated against the total number of Orgenesis shares, or, against the total number of tradable Orgenesis shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Orgenesis's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Orgenesis shares in existence, roughly 30 shares are currently held short) or 0.0326% of the tradable shares (for every 100,000 tradable Orgenesis shares, roughly 33 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Orgenesis.

Find out more about how you can short Orgenesis stock.

Orgenesis share dividends

We're not expecting Orgenesis to pay a dividend over the next 12 months.

Have Orgenesis's shares ever split?

Orgenesis's shares were split on a 1:12 basis on 15 November 2017. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Orgenesis shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Orgenesis shares which in turn could have impacted Orgenesis's share price.

Orgenesis share price volatility

Over the last 12 months, Orgenesis's shares have ranged in value from as little as $4.3 up to $8.3. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Orgenesis's is 1.2653. This would suggest that Orgenesis's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Orgenesis overview

Orgenesis Inc. , a biotech company, focusing on cell and gene therapies (CGTs). The company develops a Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. sThe company's POCare Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies worldwide. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc.

Frequently asked questions

• What percentage of Orgenesis is owned by insiders or institutions?

  Currently 8.529% of Orgenesis shares are held by insiders and 25.675% by institutions.

• How many people work for Orgenesis?

  Latest data suggests 111 work at Orgenesis.

• When does the fiscal year end for Orgenesis?

  Orgenesis's fiscal year ends in November.

• Where is Orgenesis based?

  Orgenesis's address is: 20271 Goldenrod Lane, Germantown, MD, United States, 20876

• What is Orgenesis's ISIN number?

  Orgenesis's international securities identification number is: US68619K2042

• What is Orgenesis's CUSIP number?

  Orgenesis's Committee on Uniform Securities Identification Procedures number is: 68619K105